Welcome to our dedicated page for SelectQuote SEC filings (Ticker: SLQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SelectQuote, Inc. filings document formal disclosures for a public insurance distribution and healthcare services company. Recent Form 8-K reports furnish quarterly and annual operating results, investor presentation exhibits, and segment information for Senior, Healthcare Services, Life, and SelectRx-related activity.
The company’s regulatory filings also cover capital-structure matters, including a senior secured credit facility and revolving credit facility, as well as NYSE continued-listing compliance disclosures. Governance records include annual meeting voting results for director elections, auditor ratification, and advisory executive-compensation matters, while amended event reports document corrections to previously furnished earnings materials.
SelectQuote, Inc. (SLQT) describes a technology-enabled, direct-to-consumer platform that distributes senior health, life, and auto & home insurance while expanding into healthcare services, including its SelectRx pharmacy, Healthcare Select, and chronic care management offerings. The company emphasizes use of AI and machine learning across lead acquisition, agent routing, contact-center voice technology, and customer lifecycle management to maximize lifetime value of commissions.
SelectQuote’s strategy is to prioritize higher-growth senior and healthcare services and de-emphasize Auto & Home, leveraging a large senior customer base, proprietary CRM (SelectCare) and related tools to cross-sell insurance and health services. As of June 30, 2026, SelectRx served over 109,000 active members, with facilities able to serve more than 200,000. Revenue is concentrated: for 2026, entities owned by UHC, Humana, and Aetna represented 39%, 13%, and 12% of total revenue. Senior segment revenue contributed 36% of total revenue in 2026, versus 39% in 2025 and 50% in 2024.
The company highlights extensive regulatory exposure across insurance, Medicare, pharmacy, data privacy, and telemarketing, and notes that its pharmacy and healthcare units are subject to additional healthcare fraud, abuse, and provider regulations. SelectQuote discloses significant reliance on a small group of carrier partners and acknowledges litigation risk, including a Department of Justice action alleging violations of the False Claims Act against it and other industry participants.
SelectQuote, Inc. (SLQT) reported mixed fourth-quarter and full-year fiscal 2026 results, with strong cash-flow improvement but softer growth and margins. For the fourth quarter ended June 30, 2026, consolidated revenue was $321.7 million versus $345.1 million a year earlier, and the company posted a net loss of $16.8 million versus net income of $12.9 million. However, consolidated Adjusted EBITDA rose to $11.9 million from $2.7 million, and cash used in operations improved to $3.3 million from $37.5 million.
For fiscal 2026, revenue increased to $1.6 billion from $1.5 billion, and net income grew to $62.2 million from $47.6 million, while Adjusted EBITDA declined to $109.1 million from $126.3 million. Operating cash flow turned positive at $31.9 million versus an outflow of $11.7 million, helped by Healthcare Services scale and efficiency gains. Segment-wise, fiscal 2026 revenue was $575.9 million in Senior, $844.9 million in Healthcare Services, and $186.0 million in Life.
For fiscal 2027, SelectQuote guides revenue to $1.35–$1.45 billion, Adjusted EBITDA to $90–$115 million, and expects operating cash flow of more than $60 million, citing over $30 million in anticipated annual expense savings from technology-enabled efficiencies.
SelectQuote, Inc. Chief Financial Officer Clement Ryan Moore reported multiple equity compensation transactions dated August 1, 2026. He exercised previously granted restricted stock units and price-vested units into common stock at $0.00 per share, and received new grants of 343,750 restricted stock units and 343,750 price-vested units. In connection with vesting, 80,733 shares of common stock at $0.7470 per share were withheld to satisfy tax-withholding obligations under SelectQuote's 2020 Omnibus Incentive Plan.
SelectQuote, Inc. executive Anderson Sarah Taylor, EVP, Healthcare, reported equity compensation activity on August 1, 2026. Several restricted stock unit and price-vested unit awards vested and converted into 85,322 common shares, while 24,890 shares were surrendered at $0.747 per share to satisfy withholding taxes.
On the same date, the executive received new grants of 77,000 restricted stock units and 77,000 price-vested units under the 2020 Omnibus Incentive Plan. These awards vest in three annual installments and, for PVUs, only if 60-day average closing-price thresholds including $2.50, $5.00, $7.50, $10.00, $3.13, $6.00, $9.00, $2.00, $3.00 and $4.00 are achieved during five-year performance periods and employment continues.
SelectQuote, Inc. chief accounting officer Stephanie D. Fisher reported equity compensation activity. On August 1, 2026 she converted 57,183 restricted and price-vested stock units into common shares, with 24,219 shares withheld at $0.747 per share to cover taxes. She also received grants of 101,914 restricted stock units and 101,914 price-vested units that vest in three annual installments subject to continued employment and stock price conditions.
SelectQuote, Inc. CEO Timothy Robert Danker reported multiple equity transactions dated August 1, 2026. He received grants of 600,000 Restricted Stock Units and 600,000 Price-Vested Restricted Stock Units, each representing a contingent right to one common share and vesting in three annual installments.
Existing RSUs and price-vested units covering 630,394 shares were exercised or converted into common stock at $0.00 per share, and 279,583 shares at $0.747 per share were surrendered to the issuer to satisfy withholding taxes. After these transactions, 9,398 shares are reported as held indirectly through a Mainstar Trust IRA. The filing does not indicate use of a Rule 10b5-1 trading plan.
SelectQuote, Inc. reports that Joshua Brandon Matthews, President of SelectQuote Senior, converted 150,932 restricted and price‑vested stock units into common shares at $0.0000 per share on August 1, 2026. He also received grants of 175,000 restricted stock units and 175,000 price‑vested units, each share‑for‑share with common stock and subject to multi‑year service and stock‑price vesting conditions.
SelectQuote, Inc. president Robert Clay Grant reported several equity transactions on August 1, 2026. He exercised previously granted restricted stock and price-vested units into 610,794 shares of common stock, received new awards of 575,000 RSUs and 575,000 price-vested units (PVUs), and had 195,438 shares withheld to satisfy tax obligations related to vesting. Indirect holdings are reported through Haakon Capital, LLC and multiple family trusts.
SelectQuote, Inc. chief operating officer William Thomas Grant III reported multiple equity transactions on August 1, 2026. He exercised previously granted RSUs and price-vested RSUs into 525,328 shares of common stock and had 174,642 shares withheld at $0.747 per share for taxes. He also received new grants of 500,000 restricted stock units and 500,000 price-vested restricted stock units (PVUs) with multi-year service and stock-price hurdles, and reported indirect holdings through a trust, Haakon Capital, LLC, and an IRA.
SelectQuote general counsel Daniel Allen Boulware reported multiple equity compensation transactions. On August 1, 2026 he exercised restricted and price-vested stock units into 217014 shares of common stock at $0.00 per share, with 91909 shares withheld at $0.747 for taxes. He also received grants of 218750 restricted stock units and 218750 price-vested units that vest over time and depend on stock-price performance targets, and holds 1100 shares indirectly through his spouse.